Funding news · Nov 17, 2026
NovAccel Raises ¥290M Seed to Build Domestic Ac-225 Supply Chain
NovAccel Secures ¥290 Million in Seed Funding
NovAccel, a Japanese startup based in Tsuchiura, Ibaraki, has raised ¥290 million in Seed funding. The round was backed by XTech Ventures and Inoue Co., Ltd. (株式会社イノウエ).
What NovAccel Does
NovAccel is developing a compact superconducting accelerator, known as RiSA, aimed at manufacturing medical radioisotopes. Its initial focus is Actinium-225 (Ac-225), an isotope used in targeted alpha therapy (TAT) for cancer treatment.
The company is working to build a domestic supply chain for Ac-225 in Japan. According to the company, global shortages of the isotope are constraining next-generation oncology research. NovAccel is also pursuing security of Ra-226 feedstock through participation in the IAEA Global Radium Initiative.
Development and Commercial Timeline
NovAccel has outlined two near-term milestones:
- Complete its accelerator manufacturing facility by October 2026
- Begin sample shipments in Q4 2026
Deal Context
The round is a Seed-stage raise totaling ¥290 million. XTech Ventures and Inoue Co., Ltd. participated as investors. No lead investor was disclosed.
The funding gives NovAccel capital to advance its accelerator build-out and move toward first sample shipments, positioning it as an emerging player in the medical isotope supply chain — a segment of interest to acquirers and strategic partners in radiopharma and nuclear technology.